Immuno-Oncology Application of Humanized Immune System (HIS) Mice Supporting Human Myeloid and Lymphoid Cells

Explore the application of humanized immune system (HIS) mice in immuno-oncology research through this 42-minute keynote webinar presented by Dr. Laura Griffin. Learn about the evolution of HIS models from the development of super immunodeficient CIEA NOG mice in the early 2000s to current second-generation host strains that express human cytokines and support both human innate and adaptive immune cells. Discover how these advanced models enable researchers to study immune-modulating therapeutics in the context of interactions between human myeloid and lymphoid lineages while supporting both tumor cell line xenografts (CDX) and patient-derived xenografts (PDX). Examine the specific capabilities of NOG-EXL and hIL-6 NOG host strains, which support a comprehensive range of human cell types including both myeloid and lymphoid lineages. Understand critical considerations for successful efficacy evaluation of immunotherapy treatments in HIS models, including how engraftment profiles vary by host strain and can be influenced by engraftment protocols and donor variability. Gain insights into best practices for preclinical evaluation of immune-modulating therapeutics using these sophisticated humanized mouse models that bridge the gap between basic research and clinical applications in cancer immunotherapy.